BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:“The end of KRAS cancers?”
DTSTART:20260507T121500
DTEND:20260507T131500
DTSTAMP:20260414T105042Z
UID:76583386343431403f697a8688126b3746187ddd1aaa7d6c79019f58
CATEGORIES:Conferences - Seminars
DESCRIPTION:Frank McCormick\, PhD\, FRS\, DSc (Hon)\, UCSF Helen Diller F
 amily Comprehensive Cancer Center and David A. Wood Chair of Tumor Biology
  and Cancer Research\nA Lola and John Grace Distinguished Lecture in Cance
 r Research\n\n\nFrank McCormick\, PhD\, is a Professor at the UCSF Helen D
 iller Family Comprehensive Cancer Center and holds the David A. Wood Chair
  of Tumor Biology and Cancer Research. Prior to joining the UCSF faculty\,
  Dr. McCormick pursued cancer-related work with several Bay Area biotechno
 logy firms and held positions with Cetus Corporation (Director of Molecula
 r Biology\, 1981-1990\; Vice President of Research\, 1990-1991) and Chiron
  Corporation\, where he was Vice President of Research. In 1992 he founded
  Onyx Pharmaceuticals\, a company dedicated to developing new cancer thera
 pies\, and served as its Chief Scientific Officer until 1996. At Onyx Phar
 maceuticals\, he initiated drug discovery efforts that led to the approval
  of Sorafenib in 2005 for treatment of renal cell cancer\, and for liver c
 ancer in 2007\, and the approval of ONYX-015 in 2006 in China for treatmen
 t of nasopharyngeal cancer. In addition\, Dr. McCormick’s group led to t
 he identification of the CDK4 kinase inhibitor\, Palbociclib\, approved fo
 r treating advanced breast cancer. Dr. McCormick's current research intere
 sts center on ways of targeting Ras proteins and their regulators\, includ
 ing the NF1 protein neurofibromin.\n\nDr. McCormick was Director of the He
 len Diller Family Comprehensive Cancer Center from 1997 to 2014 and he ser
 ved as President\, 2012-2013\, for the American Association for Cancer Res
 earch. Since 2013\, Dr. McCormick has led the National Cancer Institute’
 s Ras Initiative at the Frederick National Laboratories for Cancer Researc
 h overseeing the national effort to develop therapies against Ras-driven c
 ancers. Dr. McCormick was recently awarded (September 2025) the Inaugural 
 Stephenson Global Prize Award in recognition of his research and discoveri
 es that have transformed the field of RAS-driven cancers. \n\nDr. McCormi
 ck is the author of over 430 scientific publications and holds more than 2
 0 issued patents and is a Fellow of the Royal Society and a member of the 
 National Academy of Sciences.\n \n\n\n\n \n
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717 https://epfl.zoom.u
 s/j/97039045251?pwd=WDFjUGV3Y1FxeG9rTUIrOGpiUXhLQT09
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR